Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

Gene Therapy

Volumn 15, Issue 10, 2008, Pages 772-779

  Power, A T ^a   Bell, J C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ONCOLYTIC VIRUS;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; CANCER CELL; CANCER THERAPY; CELL BASED GENE THERAPY; CELL LINE; CELL MIGRATION; CELL TYPE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EX VIVO GENE TRANSFER; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IN VIVO STUDY; LEUKEMIA CELL; MAXIMUM TOLERATED DOSE; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REVIEW; SINGLE DRUG DOSE; TUMOR IMMUNITY; VESICULAR STOMATITIS VIRUS; VIRUS CELL INTERACTION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL TRANSPLANTATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EQUIDAE; HARNESS;

EID: 43049124803     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.40     Document Type: Review

References (29)

1. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5 965-976.
2. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117.
3. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
4. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-275.
5. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD et al Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007; 15: 123-130.
6. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007; 15: 1686-1693.
7. Fisher K. Striking out at disseminated metastases: The systemic delivery of oncolytic viruses. Curr Opin Mol Ther 2006; 8: 301-313.
8. Gobet R, Cerny A, Ruedi E, Hengartner H, Zinkernagel RM. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp Cell Biol 1988; 56: 175-180.
9. Leist TP, Cobbold SP, Waldmann H, Aguet M, Zinkernagel RM. Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol 1987; 138: 2278-2281.
10. Zinkernagel RM, Adler B, Holland JJ. Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol 1978; 46: 53-70.
11. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-1537.
12. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Therapy 2007; 14: 324-333.
13. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ et al. Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007; 15: 114-122.
14. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
15. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-766.
16. Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther 2007; 18: 627-641.
17. Raykov Z, Balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004; 109: 742-749.
18. Garcia-Castro J, Martinez-Palacio J, Lillo R, Garcia-Sanchez F, Alemany R, Madero L et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 2005; 12 341-349.
19. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: A new strategic alliance for a biological strike against cancer. Mol Ther 2007; 15: 660-665.
20. Bergman I, Whitaker-Dowling P, Gao Y, Griffin JA. Preferential targeting of vesicular stomatitis virus to breast cancer cells. Virology 2004; 330: 24-33.
21. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005; 65: 5292-5300.
22. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B et al Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 2005; 11: 346-352.
23. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209-214.
24. Bucheit AD, Kumar S, Grote DM, Lin Y, von MV, Cattaneo RB et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62-72.
25. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75: 2087-2096.
26. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003; 101: 2557-2562.
27. Schuurman HJ, Pierson III RN. Progress towards clinical xenotransplantation. Front Biosci 2008; 13: 204-220.
28. Huppert J, Gresland L, Lazar P. Heterogeneity of chick embryo cells with regard to Newcastle disease virus multiplication. J Gen Virol 1974; 23: 281-287.
29. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11: 1073-1081.